These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 38217526)
1. Current targeting strategies and advanced nanoplatforms for atherosclerosis therapy. Li Y; Feng Q; Wang L; Gao X; Xi Y; Ye L; Ji J; Yang X; Zhai G J Drug Target; 2024 Dec; 32(2):128-147. PubMed ID: 38217526 [TBL] [Abstract][Full Text] [Related]
2. Platelet membrane-coated nanoparticle-mediated targeting delivery of Rapamycin blocks atherosclerotic plaque development and stabilizes plaque in apolipoprotein E-deficient (ApoE Song Y; Huang Z; Liu X; Pang Z; Chen J; Yang H; Zhang N; Cao Z; Liu M; Cao J; Li C; Yang X; Gong H; Qian J; Ge J Nanomedicine; 2019 Jan; 15(1):13-24. PubMed ID: 30171903 [TBL] [Abstract][Full Text] [Related]
3. Non-proinflammatory and responsive nanoplatforms for targeted treatment of atherosclerosis. Dou Y; Chen Y; Zhang X; Xu X; Chen Y; Guo J; Zhang D; Wang R; Li X; Zhang J Biomaterials; 2017 Oct; 143():93-108. PubMed ID: 28778000 [TBL] [Abstract][Full Text] [Related]
4. Targeting the Microenvironment of Vulnerable Atherosclerotic Plaques: An Emerging Diagnosis and Therapy Strategy for Atherosclerosis. Zhang S; Liu Y; Cao Y; Zhang S; Sun J; Wang Y; Song S; Zhang H Adv Mater; 2022 Jul; 34(29):e2110660. PubMed ID: 35238081 [TBL] [Abstract][Full Text] [Related]
5. Pharmacological modulation of cell death in atherosclerosis: a promising approach towards plaque stabilization? Martinet W; Schrijvers DM; De Meyer GR Br J Pharmacol; 2011 Sep; 164(1):1-13. PubMed ID: 21418184 [TBL] [Abstract][Full Text] [Related]
6. Application of targeted therapy strategies with nanomedicine delivery for atherosclerosis. Ou LC; Zhong S; Ou JS; Tian JW Acta Pharmacol Sin; 2021 Jan; 42(1):10-17. PubMed ID: 32457416 [TBL] [Abstract][Full Text] [Related]
7. [Basic research of fibrosis on atherosclerotic plaque stability and related drug application]. Yin J; Li Q; Zhao Z; Yang Q; Li YJ; Chen Y; Wang YJ; Weng XG; Cai WY; Zhu XX Zhongguo Zhong Yao Za Zhi; 2019 Jan; 44(2):235-241. PubMed ID: 30989939 [TBL] [Abstract][Full Text] [Related]
8. Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis. Chen W; Schilperoort M; Cao Y; Shi J; Tabas I; Tao W Nat Rev Cardiol; 2022 Apr; 19(4):228-249. PubMed ID: 34759324 [TBL] [Abstract][Full Text] [Related]
9. An apoptotic body-biomimic liposome in situ upregulates anti-inflammatory macrophages for stabilization of atherosclerotic plaques. Wu Y; Zhang Y; Dai L; Wang Q; Xue L; Su Z; Zhang C J Control Release; 2019 Dec; 316():236-249. PubMed ID: 31672624 [TBL] [Abstract][Full Text] [Related]
10. Nanoparticles as Drug Delivery Systems for the Targeted Treatment of Atherosclerosis. Pang AS; Dinesh T; Pang NY; Dinesh V; Pang KY; Yong CL; Lee SJJ; Yip GW; Bay BH; Srinivasan DK Molecules; 2024 Jun; 29(12):. PubMed ID: 38930939 [TBL] [Abstract][Full Text] [Related]
11. Sugar-based amphiphilic nanoparticles arrest atherosclerosis in vivo. Lewis DR; Petersen LK; York AW; Zablocki KR; Joseph LB; Kholodovych V; Prud'homme RK; Uhrich KE; Moghe PV Proc Natl Acad Sci U S A; 2015 Mar; 112(9):2693-8. PubMed ID: 25691739 [TBL] [Abstract][Full Text] [Related]
12. Nanotherapeutic Shots through the Heart of Plaque. Kanthi Y; de la Zerda A; Smith BR ACS Nano; 2020 Feb; 14(2):1236-1242. PubMed ID: 31986012 [TBL] [Abstract][Full Text] [Related]
14. Engineering Nanoplatforms for Theranostics of Atherosclerotic Plaques. Liu Y; Jiang Z; Yang X; Wang Y; Yang B; Fu Q Adv Healthc Mater; 2024 Jun; 13(16):e2303612. PubMed ID: 38564883 [TBL] [Abstract][Full Text] [Related]
15. Nano-Systems for Advanced Therapeutics and Diagnosis of Atherosclerosis. Gaurav C; Saurav B; Goutam R; Goyal AK Curr Pharm Des; 2015; 21(30):4498-508. PubMed ID: 26377651 [TBL] [Abstract][Full Text] [Related]
16. Nanoparticle Functionalization with Platelet Membrane Enables Multifactored Biological Targeting and Detection of Atherosclerosis. Wei X; Ying M; Dehaini D; Su Y; Kroll AV; Zhou J; Gao W; Fang RH; Chien S; Zhang L ACS Nano; 2018 Jan; 12(1):109-116. PubMed ID: 29216423 [TBL] [Abstract][Full Text] [Related]
17. Delayed progression of atherosclerosis and cardiovascular events in asymptomatic patients with atherosclerotic plaques: 3-year prevention with the supplementation with Pycnogenol®+Centellicum®. Belcaro G; Cesarone MR; Scipione C; Scipione V; Dugall M; Shu H; Peterzan P; Corsi M; Luzzi R; Hosoi M; Feragalli B; Cotellese R Minerva Cardioangiol; 2020 Feb; 68(1):15-21. PubMed ID: 31625707 [TBL] [Abstract][Full Text] [Related]
18. Targeting Nanoplatform for Atherosclerosis Inhibition and Degradation via a Dual-Track Reverse Cholesterol Transport Strategy. Chen Z; Zhu Q; Li D; Lv Q; Fu G; Ma B; Zhang W Small; 2024 Feb; 20(7):e2306457. PubMed ID: 37803917 [TBL] [Abstract][Full Text] [Related]
19. Perillaldehyde prevents the formations of atherosclerotic plaques through recoupling endothelial nitric oxide synthase. Yu L; Liu H J Cell Biochem; 2018 Dec; 119(12):10204-10215. PubMed ID: 30171746 [TBL] [Abstract][Full Text] [Related]
20. Hyaluronan Nanoparticles Selectively Target Plaque-Associated Macrophages and Improve Plaque Stability in Atherosclerosis. Beldman TJ; Senders ML; Alaarg A; Pérez-Medina C; Tang J; Zhao Y; Fay F; Deichmöller J; Born B; Desclos E; van der Wel NN; Hoebe RA; Kohen F; Kartvelishvily E; Neeman M; Reiner T; Calcagno C; Fayad ZA; de Winther MPJ; Lutgens E; Mulder WJM; Kluza E ACS Nano; 2017 Jun; 11(6):5785-5799. PubMed ID: 28463501 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]